NPM1 mutation (most commonly type-A: c.860_863dupTCTG / p.W288fs) in AML — ~30% of adult...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | RF-AML-NPM1-MUT-FAVORABLE |
|---|---|
| Type | Red flag |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-AML |
| Sources | SRC-ELN-AML-2022 SRC-ESMO-AML-2020 SRC-NCCN-AML-2025 |
Red Flag Origin
| Definition | NPM1 mutation (most commonly type-A: c.860_863dupTCTG / p.W288fs) in AML — ~30% of adult AML; ~50% of cytogenetically normal AML. ELN-2022 favorable risk when NPM1-mutated WITHOUT FLT3-ITD; standard 7+3 induction first-line (no upfront alloHCT in CR1; consolidation HiDAC × 3-4 cycles is curative-intent). MRD qPCR (NPM1-mut transcript) for monitoring. |
|---|---|
| Clinical direction | de-escalate |
| Category | high-risk-biology |
| Shifts algorithm | ALGO-AML-1L |
Trigger Logic
{
"all_of": [
{
"any_of": [
{
"finding": "npm1_mutation",
"value": true
},
{
"finding": "npm1_status",
"value": "mutated"
},
{
"finding": "npm1_type_a",
"value": true
}
]
},
{
"any_of": [
{
"finding": "flt3_itd",
"value": false
},
{
"finding": "flt3_itd_status",
"value": "negative"
}
]
}
],
"type": "composite_score"
}
Notes
De-escalate direction reflects "do NOT intensify to upfront alloHCT" — favorable-risk patients receive standard chemo with curative intent; alloHCT reserved for MRD-positive after consolidation OR early relapse. NPM1-mut + FLT3-ITD high-allelic-ratio downgrades to intermediate (and now adverse per ELN-2022 if NPM1-WT). MRD-NPM1 qPCR threshold ≥2-log reduction = molecular response; MRD-positive after consolidation → consider alloHCT. Menin inhibitors (revumenib, ziftomenib) — investigational R/R NPM1-mut. RF coexists with RF-AML-FLT3-ACTIONABLE (different axes — NPM1+FLT3-ITD case fires both).
Used By
Algorithms
ALGO-AML-1L- ALGO-AML-1L